Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
133 hedge funds and large institutions have $1.14B invested in Alpine Immune Sciences Inc in 2023 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 62 increasing their positions, 10 reducing their positions, and 9 closing their positions.
520% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 10
511% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 9
460% more call options, than puts
Call options by funds: $140K | Put options by funds: $25K
116% more capital invested
Capital invested by funds: $526M → $1.14B (+$611M)
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
51% more funds holding
Funds holding: 88 → 133 (+45)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$19.6M |
| 2 |
Morgan Stanley
New York
|
+$19.2M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$17M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$21.5M |
| 2 |
AG
Artal Group
Luxembourg
|
-$15.9M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$7.6M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$7.53M |
| 5 |
TLP
Tri Locum Partners
New York
|
-$3.6M |
ALPN Hedge Fund Activity: Q4 2023 in Review
133 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q4 2023, worth a combined $1.14B — up 116% from $526M a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new ALPN positions and 9 closed out — a net gain of 46 holders — while 62 added to existing stakes and 10 trimmed.
The largest buyer was Lynx1 Capital Management, adding an estimated $19.6M. The largest seller was OrbiMed, cutting an estimated $21.5M.
- 133 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q4 2023, up from 88 in Q3 2023.
- Funds reported $1.14B of Alpine Immune Sciences Inc stock for Q4 2023, up 116% quarter-over-quarter.
- 55 funds opened new Alpine Immune Sciences Inc positions in Q4 2023 and 9 closed out, a net change of +46 holders.
- The largest Alpine Immune Sciences Inc buyer in Q4 2023 was Lynx1 Capital Management, an estimated $19.6M added.
- The largest Alpine Immune Sciences Inc seller in Q4 2023 was OrbiMed, an estimated $21.5M sold.
Based on aggregated 13F filings for Q4 2023.